You have free access to this content

Clinical Liver Disease

Cover image for Clinical Liver Disease

Edited By: Michael Lucey, MD

Online ISSN: 2046-2484

Associated Title(s): Hepatology, Liver Transplantation

Recently Published Issues

See all

  • Current Issue:July 2014

    Volume 4, Issue 1

    Special Issue: Drug-Induced Liver Injury (DILI)

  • June 2014

    Volume 3, Issue 6

    Special Issue: Vascular Disorders

  • May 2014

    Volume 3, Issue 5

    Special Issue: Heavy Metals and the Liver

  • April 2014

    Volume 3, Issue 4

    Special Issue: Autoimmune Liver Disease, Part 4

  • March 2014

    Volume 3, Issue 3

    Special Issue: Autoimmune Liver Disease, Part 3

Drug-Induced Liver Injury (DILI)

Guest Edited by: Robert J. Fontana, M.D.

Herbal and Dietary Supplement Hepatotoxicity
Vinaya C. Maddukuri, M.D., and Herbert L. Bonkovsky, M.D.
Herbal and dietary supplements (HDS) include vitamins, minerals, herbs or other plant materials, and some can cause hepatotoxicity. HDS hepatotoxicity has risen almost threefold over the past decade, read more to learn what clinicians need to look for.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME



Causality Assessment: Which Is Best—Expert Opinion or RUCAM?
James H. Lewis, M.D.
Causality assessment for DILI began more as an art form than a science, and while methods have improved, there is still often an element of "guilt by association." Dr. James Lewis reviews the benefits and limitations of DILI causality assessment.
Read the full textListen to the article presentationAnswer questions and earn CME



Incidence and Outcomes of DILI in Western Patients
Einar S. Bjornsson, M.D., Ph.D.
In its most severe form, DILI can lead to acute liver failure with associated mortality and need for liver transplantation. While most previous cohort studies have been retrospective and likely underestimate this difficult-to-diagnose adverse drug reaction, findings from more recent research are providing new insight into the etiologies and outcomes of DILI in Western countries.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME



Liver Histology in the Diagnosis and Prognosis of Drug-Induced Liver Injury
David E. Kleiner, M.D., Ph.D.
Liver Histology in the Diagnosis and Prognosis of Drug-Induced Liver Injury
Unlike with some other more prevalent liver diseases, there is no clearly defined role or professional guidelines for the use of liver biopsy in DILI, presenting unique challenges to the clinician as well as the pathologist. Dr. Kleiner reviews pattern of injury, severity, and prognosis through biopsy evaluation.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME



LiverTox: An Online Information Resource and a Site for Case Report Submission on Drug-Induced Liver Injury
Jose Serrano M.D., Ph.D.
LiverTox
As a part of a long-term initiative in promoting basic and clinical research on DILI, the Liver Disease Research Branch of the NIDDK—in collaboration with the National Library of Medicine (NLM) and the DILIN—has created the LiverTox website www.livertox.gov to provide up-to-date, comprehensive clinical information on DILI for both health care providers and the public.
Read the full text.Watch the author interview.Listen to the article presentation.Answer questions and earn CME.

Series on New Treatments for Hepatitis C

Guest Edited by Donald M. Jensen, M.D., F.A.C.P.


New All-Oral HCV Therapies for Genotype 1: A Final Good-bye to Interferon
Anna S.F. Lok, M.D.
With more than 30 direct-acting antiviral agents (DAAs) in clinical trials, the hepatitis C community anticipates that the right combinations of DAAs will emerge, permitting treatment of hepatitis C virus (HCV) genotype 1 with interferon (IFN)-free regimens.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME



New AASLD/IDSA HCV Practice Guidelines: An Online Resource
Gary L. Davis, M.D.
As treatment for Hepatitis C rapidly evolves, how are recommendations being developed, and how they will be updated over time? Read or listen to Dr. Gary Davis' review to learn more about how organiziations like the AASLD are working to keep clinicians informed with the best and most up-to-date guidelines.
Read the full textListen to the article presentationAnswer questions and earn CME



Recent FDA Approval of Sofosbuvir and Simeprevir. Implications for Current HCV Treatment
M. Valerie Lin, M.D., and Raymond Chung, M.D.
Drs. Lin and Chung break down what clinicians need to know about Sofosbuvir and Simeprevir: from mechanisms of action, to approved indications, use outside approved indications, and treatment challenges.
Read the full textListen to the article presentationAnswer questions and earn CME

Test your knowledge! Use the Hepatitis C Self Assessment to complete board-style practice questions.

More from Drug-Induced Liver Injury (DILI)

Acetaminophen Overdose: What Practitioners Need to Know
Khurram Bari, M.D., and Robert J. Fontana, M.D.
Acetaminophen overdose is the most common cause of drug-induced liver injury in the United States, with about 60,000 cases reported each year, and also accounts for nearly 50% of adult acute liver failure (ALF) cases. Learn about epidemiology, clinical presentation, treatment, prognosis, and steps being taken to prevent overdose.
Read the full text.Watch the author interview.Listen to the article presentation.Answer questions and earn CME.



Overview of Drug-Induced Liver Injury in China
Gui-Qiang Wang, M.D., Yong-Qiong Deng, M.D., and Feng-Qin Hou, M.S.
Differences in the underlying diseases and disorders in Eastern populations compared to Western populations, as well as the frequent use of traditional Chinese medicine, mean that the epidemiology and etiologies of DILI may differ in China compared to other parts of the world. Learn from experts in the region about the epidemiology, etiologies, and management of DILI in mainland China.
Read the full text.Watch the author interview.Listen to the article presentation.Answer questions and earn CME.



iTunes logo

Access CLD on the go.
Listen to the author interviews and readings of the full articles by subscribing to the iTunes podcast.



Find CLD on Facebook

Follow CLD on Twitter

SEARCH

SEARCH BY CITATION